Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mercaptamine - NovaBiotics

Next Previous
Drug Profile

Mercaptamine - NovaBiotics

Alternative Names: Cysteamine - NovaBiotics; Lynovex; Mufrosyn®; NM 001 - NovaBiotics; NM-002; NM003; Nylexa

Latest Information Update: 20 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NovaBiotics
  • Class Anti-inflammatories; Antibacterials; Antidotes; Hepatoprotectants; Mercaptoethylamines; Mucolytics; Small molecules
  • Mechanism of Action Glutathione synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Community-acquired pneumonia
  • Phase II Cystic fibrosis-associated respiratory tract infections

Most Recent Events

  • 20 Feb 2025 Preclinical development in Cystic-fibrosis-associated-respiratory-tract-infections in United Kingdom (Inhalation, Powder) (NovaBiotics pipeline, February 2025)
  • 20 Feb 2025 Preclinical development is ongoing in Cystic-fibrosis-associated-respiratory-tract-infections in United Kingdom (PO, Capsule) (NovaBiotics pipeline, February 2025)
  • 20 Feb 2025 Phase-III clinical trials in Community-acquired pneumonia (unspecified route) (NovaBiotics pipeline, February 2025):

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top